Cross-talk between glycogen synthase kinase 3β (GSK3β) and p38MAPK regulates myocyte enhancer factor 2 (MEF2) activity in skeletal and cardiac muscle

Journal of Molecular and Cellular Cardiology

Volumn 54, Issue 1, 2013, Pages 35-44

  Dionyssiou, M G ^a   Nowacki, N B ^a   Hashemi, S ^a   Zhao, J ^a   Kerr, A ^a   Tsushima, R G ^a   McDermott, J C ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

Glycogen synthase kinase 3 beta; Myocyte enhancer factor 2; P38MAPK

Indexed keywords

CREATINE KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOCYTE ENHANCER FACTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOMYOCYTE HYPERTROPHY; COMPUTER MODEL; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HEART MUSCLE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MUSCLE DEVELOPMENT; MUSCLE HYPERTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RAT; SKELETAL MUSCLE; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; CELL LINE; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE EXPRESSION REGULATION; GENES, REPORTER; GLYCOGEN SYNTHASE KINASE 3; IMIDAZOLES; LUCIFERASES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SKELETAL; MYOBLASTS; MYOBLASTS, SKELETAL; MYOCARDIUM; MYOCYTES, CARDIAC; MYOGENIC REGULATORY FACTORS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIDINES; SIGNAL TRANSDUCTION; THIAZOLES; TRANSCRIPTIONAL ACTIVATION; UREA;

MUS;

EID: 84870164050     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.10.013     Document Type: Article

References (55)

1. Takahashi M., Okubo N., Chosa N., Takahashi N., Ibi M., Kamo M., et al. Fibroblast growth factor-1-induced ERK1/2 signaling reciprocally regulates proliferation and smooth muscle cell differentiation of ligament-derived endothelial progenitor cell-like cells. Int J Mol Med 2012, 29(3):357-364.
2. Huang C., Jacobson K., Schaller M.D. MAP kinases and cell migration. J Cell Sci 2004, 117:4619-4628.
3. Tamura K., Sudo T., Senftleben U., Dadak A.M., Johnson R., Karin M. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 2000, 102(2):221-231.
4. Aouadi M., Bost F., Caron L., Laurent K., Le Marchand Brustel Y., Binétruy B. p38 mitogen-activated protein kinase activity commits embryonic stem cells to either neurogenesis or cardiomyogenesis. Stem Cells 2006, 25(5):1399-1406.
5. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signaling pathways in cancer. Oncogene 2007, 26:3279-3290.
6. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001, 3:1009-1013.
7. Haq S., Choukroun G., Kang Z.B., Ranu H., Matsui T., Rosenzweig A., et al. Glycogen synthase kinase 3β is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 2000, 151:117-129.
8. Cox D.M., Du M., Marback M., Yang E.C., Chan J., Siu K.W., et al. Phosphorylation motifs regulating the stability and function of myocyte enhancer factor 2A. J Biol Chem 2003, 278(17):15297-15303.
9. Pollock R., Treisman R. Human SRF-related proteins: DNA-binding properties and potential regulatory targets. Genes Dev 1991, 5:2327-2341.
10. Potthoff M.J., Olson E.N. MEF2: a central regulator of diverse developmental programs. Development 2007, 134(23):4131-4140.
11. Zhu B., Gulick T. Phosphorylation and alternative pre-mRNA splicing converge to regulate myocyte enhancer factor 2C activity. Mol Cell Biol 2004, 24(18):8264-8275.
12. Zhu B., Ramachandran B., Gulick T. Alternative pre-mRNA splicing governs expression of a conserved acidic transactivation domain in myocyte enhancer factor 2 factors of striated muscle and brain. J Biol Chem 2005, 280(31):28749-28760.
13. Angelelli C., Magli A., Ferrari D., Ganassi M., Matafora V., Parise F., et al. Differentiation-dependent lysine 4 acetylation enhances MEF2C binding to DNA in skeletal muscle cells. Nucleic Acids Res 2008, 36(3):915-928.
14. Grégoire S., Xiao L., Nie J., Zhang X., Xu M., Li J., et al. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol 2007, 27(4):1280-1295.
15. Ma K., Chan J.K., Zhu G., Wu Z. Myocyte enhancer factor 2 acetylation by p300 enhances its DNA binding activity, transcriptional activity, and myogenic differentiation. Mol Cell Biol 2005, 25(9):3575-3582.
16. Gregoire S., Yang X.J. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Mol Cell Biol 2005, 25(6):2273-2287.
17. Yang X.J., Gregoire S. A recurrent phospho-sumoyl switch in transcriptional repression and beyond. Mol Cell 2006, 23(6):779-786.
18. Molkentin J.D., Li L., Olson E.N. Phosphorylation of the MADS-Box transcription factor MEF2C enhances its DNA binding activity. J Biol Chem 1996, 271:17199-17204.
19. Yang C.C., Ornatsky O.I., McDermott J.C., Cruz T.F., Prody C.A. Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1. Nucleic Acids Res 1998, 26:4771-4777.
20. Kato Y., Kravchenko V.V., Tapping R.I., Han J., Ulevitch R.J., Lee J.D. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 1997, 16:7054-7066.
21. Puri P.L., Wu Z., Zhang P., Wood L.D., Bhakta K.S., Han J., et al. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev 2000, 14:574-584.
22. Han J., Molkentin J. Regulation of MEF2 by P38 MAPK and its Implication in Cardiomyocyte Biology. TCM 2000, 10(1):19-22.
23. Munoz J.P., Collao A., Chiong M., Maldonado C., Adasme T., Carrasco L., et al. The transcription factor MEF2C mediates cardiomyocyte hypertrophy induced by IGF-1 signaling. BBRC 2009, 388:155-160.
24. de Angelis L., Zhao J., Andreucci J.J., Olson E.N., Cossu G., McDermott J.C. Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2 signaling pathway. Dev Biol 2005, 283:171-179.
25. Du M., Perry R.L., Nowacki N.B., Gordon J.W., Salma J., Zhao J., et al. Protein kinase A represses skeletal myogenesis by targeting myocyte enhancer factor 2D. Mol Cell Biol 2008, 28(9):2952-2970.
26. Cohen P., Frame S. The renaissance of GSK3. Nat Rev 2001, 2:769-776.
27. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003, 116(7):1175-1186.
28. Force T., Woodgett J.R. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 2009, 284(15):9643-9647.
29. Veeranna Amin N.D., Ahn N.G., Jaffe H., Winters C.A., Grant P., Pant H.C. Mitogen-activated protein kinases (Erk1,2) phosphorylate Lys-Ser-Pro (KSP) repeats in neurofilament proteins NF-H and NF-M. J Neurosci 1998, 18(11):4008-4021.
30. Berling B., Wille H., Röll B., Mandelkow E.M., Garner C., Mandelkow E. Phosphorylation of microtubule-associated proteins MAP2a, b and MAP2c at Ser136 by proline-directed kinases in vivo and in vitro. Eur J Cell Biol 1994, 54:120-130.
31. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen Synthase Kinase 3: more than a namesake. Br J Pharmacol 2009, 156:885-898.
32. Dorn G.W., Force T. J Clin Invest 2005, 115:527-537.
33. Van der Velden J.L.J., Langen R.C., Kelders M.C., Wouters E.F., Janssen-Heininger Y.M., Schols A.M. Inhibition of glycogen synthase kinase-3beta activity is sufficient to stimulate myogenic differentiation. Am J Physiol Cell Physiol 2006, 290:C453-C462.
34. Chun Y.K., Kim J., Kwon S., Choi S.H., Hong F., Moon K., et al. Phosphatidylinositol 3-kinase stimulates muscle differentiation by activating p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 2000, 276:502-507.
35. Rampalli S., Li L., Mak E., Ge K., Brand M., Tapscott S.J., et al. p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase complexes to specific genes during differentiation. Nat Struct Mol Biol 2007, 14(12):1150-1156.
36. Serra C., Palacios D., Mozzetta C., Forcales S.V., Morantte I., Ripani M., et al. Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell 2007, 28(2):200-213.
37. Abell A.N., Granger D.A., Johnson G.L. MEKK4 stimulation of p38 and JNK activity is negatively regulated by GSK3beta. J Biol Chem 2007, 282(42):30476-30484.
38. Thornton T.M., Pedraza-Alva G., Deng B., Wood C.D., Aronshtam A., Clements J.L., et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008, 320(5876):667-670.
39. Allard D., Figg N., Bennett M.R., Littlewood T.D. Akt regulates the survival of vascular smooth muscle cells via inhibition of FoxO3a and GSK3. J Biol Chem 2008, 283(28):19739-19747.
40. Vyas D.R., Spangenburg E.E., Abraha T.W., Childs T.E., Booth F.W. GSK-3beta negatively regulates skeletal myotube hypertrophy. Am J Physiol Cell Physiol 2002, 283(2):C545-C551.
41. Bhat R., Xue Y., Berg S., Hellberg S., Ormö M., Nilsson Y., et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003, 278:45937-45945.
42. Yost C., Torres M., Miller J.R., Huang E., Kimelman D., Moon R.T. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996, 10:1443-1454.
43. Ornatsky O.I., Cox D.M., Tangirala P., Andreucci J.J., Quinn Z.A., Wrana J.L., et al. Post-translational control of the MEF2A transcriptional regulatory protein. Nucleic Acids Res 1999, 27:2646-2654.
44. Chen G., Bower K.A., Ma C. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004, 18:1162-1164.
45. Lin Q., Schwarz J., Bucana C., Olson E.N. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 1997, 276(5317):1404-1407.
46. Lin Q., Lu J., Yanagisawa H., Webb R., Lyons G.E., Richardson J.A., et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 1998, 125(22):4565-4574.
47. Naya F.J., Black B.L., Wu H., Bassel-Duby R., Richardson J.A., Hill J.A., et al. Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat Med 2002, 8(11):1303-1309.
48. Kim Y., Phan D., van Rooij E., Wang D.Z., McAnally J., Qi X., et al. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest 2008, 118(1):124-132.
49. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003, 65:45-79.
50. Luckey S.W., Walker L.A., Smyth T., Mansoori J., Messmer-Kratzsch A., Rosenzweig A., et al. The role of Akt/GSK-3beta signaling in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2009, 46(5):739-747.
51. Matsuda T., Zhai P., Maejima Y., Hong C., Gao S., Tian B., et al. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc Natl Acad Sci 2008, 105(52):20900-20905.
52. Förster K., Richter H., Alexeyev M.F., Rosskopf D., Felix S.B., Krieg T. Inhibition of glycogen synthase kinase 3beta prevents peroxide-induced collapse of mitochondrial membrane potential in rat ventricular myocytes. Clin Exp Pharmacol Physiol 2010, 37(7):684-688.
53. Naya F.J., Wu C., Richardson J.A., Overbeek P., Olson E.N. Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. Development 1999, 126:2045-2052.
54. Saunders KE, Goodwin GM. New Approaches in the Treatment of Bipolar Depression. Curr Top Behav Neurosci; in press.
55. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res; in press.